miR-218-5p靶向PDE7A调节人非小细胞肺癌A549细胞的糖酵解

目的:探究miR-218-5p靶向磷酸二酯酶7A(PDE7A)调节人非小细胞肺癌(NSCLC)A549细胞糖酵解过程的机制。方法:常规培养A549细胞,用Lipo3000将miR-218-5pmimic、mimic-NC、PDE7A过表达质粒(PDE7A-oe)和PDE7A对照质粒(PDE7A-NC)转染A549细胞,记为miR-218-5pmimic组、mimic-NC组、PDE7A-oe组和PDE7A-NC组。qPCR法验证转染效率,WB法检测糖酵解关键酶蛋白的表达,葡萄糖测定法和乳酸生成测定法检测各转染组A549细胞中2脱氧葡萄糖和乳酸含量,双萤光素酶报告基因实验验证miR-218-5p与PDE7A靶向结合关系,用TCGA数据库数据分析PDE7AmRNA在肺癌组织中的表达水平。结果:在A549细胞中成功地过表达了miR-218-5p(P<0.01)。过表达miR-218-5p均能显著抑制A549细胞中PDE7A、HK2、PKM2蛋白的表达(均P<0.01)、葡萄糖摄取量和乳酸生成量(均P<0.01)。过表达PDE7A均可显著促进A549细胞中PDE7A、HK2、PKM2蛋白的表达(均P<0.01),以及葡萄糖摄取量和乳酸生成量(均P<0.01)。A549细胞中miR-218-5p可与PDE7AmRNA的3´-UTR直接结合。数据库数据分析结果显示,PDE7AmRNA在肺鳞状细胞癌组织中呈高表达(P<0.01)。结论:miR-218-5p靶向PDE7A调控A549细胞中HK2和PKM2的表达水平,进而抑制糖酵解过程,miR-218-5p/PDE7A可能是NSCLC临床诊断和治疗的潜在靶点。

PDE4B专一性抑制剂选择性的起源

采用分子动力学模拟和结合自由能计算研究了PDE4B抑制剂选择性的起源.首先,探索了模拟时间、溶质介电常数、配体的电荷方案和结合自由能的计算方法对结合自由能预测值准确度的影响,确定最佳模拟条件为:模拟时间40~50 ns,溶质介电常数ε=2,采用MM/GBSA方法以及RESP配体电荷计算方案.接着,通过能量分解分析了抑制剂A33与PDE4B/PDE4D的相互作用,发现PDE4B酶上的Ile410、Gln443、Phe446和Phe506对抑制剂的选择性识别贡献较大.最后,通过位点突变方法探索了PDE4B的CR3螺旋上的Leu502残基对A33选择性所起的作用.当前的工作为设计高活性、高选择性的PDE4B抑制剂提供了有价值的结构与活性关系信息.

Effect of Icariin on Cyclic GMP Levels and on the mRNA Expression of cGMP-binding cGMP-specific Phosphodiesterase (PDE5) in Penile Cavernosum

Summary： To further investigate the mechanisms of action of icariin （ICA）, we assessed the effects of ICA on the in vitro formation of cGMP and cAMP in isolated rabbit corpus cavernosum. Isolated segments of rabbit corpus cavernosum were exposed to increasing concentrations of ICA and the dose-dependent accumulation of cGMP and cAMP was determined in the tissues samples by means of ^125I radioimmunoassay. Responses of the isolated tissues preparations to ICA were compared with those obtained with the reference compounds sildenafil （Sild）. Furthermore, the effects of ICA on the mRNA expression of specific cGMP-binding phosphodiesterase type Ⅴ （PDE5） in rat penis were also observed. After incubation with ICA for 6 h or 14 h respectively, the levels of PDE5 mRNA were examined by reverse transcriptase polymerase chain reaction （RT-PCR）. The results showed that ICA increased cGMP concentrations directly （P〈0.05）, but there was no significant effect on cAMP concentrations （P〉0.05）. In the presence of sodium nitroprusside （SNP）, a stimulatory agent of cGMP, both ICA and Sild increased cGMP concentrations with increasing dose （P〈0.01）. Their EC50 was 4.62 （ICA） and 0.42 （Sild） μmol/L respectively. Under the same condition, ICA and Sild unaltered cAMP level significantly （P〉0.05）. There were PDE5A 1 and PDE5A2 mRNA expressions in rat cor- pus cavernosum with PDE5A2 being the dominant isoform. ICA could obviously inhibit these two isoforms mRNA expression in rat penis, and decrease PDE5A1 more pronouncedly （P〈 0.01）. The present study indicated that the aphrodisiac mechanisms of icariin involved the NO-cGMP signal transduction pathway, with increasing cGMP levels in the corpus cavernosum smooth muscle. The inhibitory effect of icariin on PDE5 mRNA expression, especially on PDE5A1, might account for its molecular mechanisms for its long-term activity.

变分分数阶PDE的自适应图像保边缘去噪方法

为了优化图像去噪过程中的边缘保真问题,本文以ROF模型及其改进模型为基础,以分数阶变分偏微分方程方法为工具,通过构造自适应的边缘检测函数,提出了一种能更好地保护图像的边缘特征,有利于纹理细节保持和“阶梯效应”抑制的基于自适应分数阶变分PDE的图像去噪模型,并以标准图像测试了新模型的去噪效果。实验结果表明:与同类方法相比,新方法可以更加有效地提高图像的信噪比;从去噪前后的图像差可以看出,新方法在去噪的同时更好地保护了图像的边缘特征及纹理细节信息。文中提出的方法可以用于遥感成像、医学图像处理及地震图像处理等领域。

基于Matlab PDE工具箱的土体冻结温度场模拟研究

分析并运用Matlab PDE tool模拟模型槽土体冻结的温度场并验证模拟值的准确性。首先,通过合理的边界假设,使三维的模型槽土体冻结热传导问题转化为二维空间;然后,运用Matlab PDE tool进行模拟并对比测温点的模拟温度和实测温度。结果表明:土体冻结中温度场导热可以通过Matlab PDE tool模拟,且操作简单易于掌握;测温点模拟值的准确性与测温点距边界距离和冻结时间有关。

PDE Standardization Analysis and Solution of TypicalMechanics Problems

A numerical approach is an effective means of solving boundary value problems(BVPs).This study focuses on physical problems with general partial differential equations(PDEs).It investigates the solution approach through the standard forms of the PDE module in COMSOL.Two typical mechanics problems are exemplified:The deflection of a thin plate,which can be addressed with the dedicated finite element module,and the stress of a pure bending beamthat cannot be tackled.The procedure for the two problems regarding the three standard forms required by the PDE module is detailed.The results were in good agreement with the literature,indicating that the PDE module provides a promising means to solve complex PDEs,especially for those a dedicated finite element module has yet to be developed.

A Novel Method for Linear Systems of Fractional Ordinary Differential Equations with Applications to Time-Fractional PDEs

This paper presents an efficient numerical technique for solving multi-term linear systems of fractional ordinary differential equations(FODEs)which have been widely used in modeling various phenomena in engineering and science.An approximate solution of the system is sought in the formof the finite series over the Müntz polynomials.By using the collocation procedure in the time interval,one gets the linear algebraic system for the coefficient of the expansion which can be easily solved numerically by a standard procedure.This technique also serves as the basis for solving the time-fractional partial differential equations(PDEs).The modified radial basis functions are used for spatial approximation of the solution.The collocation in the solution domain transforms the equation into a system of fractional ordinary differential equations similar to the one mentioned above.Several examples have verified the performance of the proposed novel technique with high accuracy and efficiency.

Purification of γ-Subunits Phosphodiesterase （γ-PDE6） Protein

Phosphodiesterase （PDE） exist various forms for the different structure and property, which is one of key components of light receptors in retinal rod cells. In this paper, cloning the DNA of T-subunits Phosphodiesterase （γ-PDE6） from cDNA library, constructing the corresponding recombinant plasmid, and purification of the protein after initial expression was studied.

Associations of Two Polymorphic Loci: A HinfⅠLocus of the Porcine Subunit C of Succinate Dehydrogenase Complex (SDHC) Gene and A MspⅠLocus of the Porcine Rod cGMP-Phosphodiesterase γ-Subunit (PDE6G) Gene

A Hinf Ⅰ locus of the porcine subunit C of succinate dehydrogenase complex (SDHC) gene and a Msp Ⅰ locus of theporcine rod cGMP-phosphodiesterase γ-subunit (PDE6G) gene had been reported before, but the association analysisbetween the different genotypes and the traits had not been done. 300 Large White × Meishan F2 pigs were used asexperimental materials to performe the PCR-RFLP analysis and association analysis for the two loci, results revealed thatthe polymorphism of the porcine subunit C of succinate dehydrogenase complex (SDHC) gene was significantly associatedwith the traits which included the carcass length, the estimated lean meat percentage, the estimated backfat thickness atlast rib, the estimated backfat thickness at last 3-4th rib, the fat meat weight, the fat meat percentage, the lean meat weight,the lean meat percentage, the ratio of lean meat to fat meat, the leaf fat weight, the backfat thickness at shoulder, thebackfat thickness at thorax-Waist, the backfat thickness at 6-7th thorax and the average daily gain. Seven other traits, themeat color value (Biceps femoris, BF), the meat marbling (Biceps femoris, BF), the water moisture (Longissimus dorsi, LD),the bone weight, the bone percentage, the loin eye width and the loin eye area, were found to be significantly correlatedwith the polymorphism of the porcine rod cGMP-phosphodiesterase γ-subunit (PDE6G) gene. Based on these results, itis necessary to apply the two genes as candidate genes to marker assistant selection (MAS) in pig breeding.

Advances in phosphodiesterase （PDE） research： clinical potentials of PDE4 inhibitors in Alzheimer＇ s disease and alcoholism

PDE is a supeffamily of enzymes that break down the important second messengers cyclic AMP （cAMP） PDE4 is the most important fami- and cyclic GMP （cGMP）. There are 11 PDE families （ PDEI-11 ） ; among them, ly in the control of intracellular cAMP signaling. It has been established that PDE4 is an essential player in the me- diation of AD and alcoholism. Chronic alcohol consumption can cause alcohol-related dementia and 50% - 75% of detoxified alcoholics have memory or cognition impairment. The lecture will focus on the unique role of PDE4 and its isoforms （PDE4A-D） in mediating AD and alcoholism and the cellular mechanisms involved. Specifically, using mice deficient in PDE4A, PDE4B, or PDE4D, and their wild type （WT） controls, it was found that PDE4Adeficiencydecreased alcohol intake and preference and reversed Abeta42-induced memory deficits. In con- trast, deficiency of PDE4B only mimicked the ability of PDE4A-deficiency to reduce alcohol consumption, while deficiency of PDE4D only reversed Abeta42-induced memory deficits. In addition, levels of cAMP and phospho- CREB （pCREB） were increased in the hippocampus of mice deficient in PDE4A or PDE4D, which also produced reversal of Abeta42-induced decreases in pCREB. These datasuggest that PDE4 isoforms have different roles in me-diating alcohol-drinking behavior and memoryin Alzheimer＇ s disease, which are mediated by cAMP/CREB signa- ling. The results indicate PDE4A as a potential new target for alcohol-related dementia, although studies with ani- mal models of alcohol-related dementia are needed to clarify this.

The Analysis of Primer Gene of Phosphodiesterase Type 5 (PDE5) on Erectyle Dysfungction

Backround: Erectile dysfunction (ED) is the inability of male reproductive organs within sexual intercourse caused by neurogenic and hormonal disorders. There are some causes of ED such as hypertension, stress, neurological disorders, stroke, diabetes, atherosclerosis, lifestyle, alcohol, smoking, and age-related hormonal decline can cause infertility. The natural treatment of sexual dysfunction through aphrodisiac activity of the plant is to increase sexual hormones, spermatogenesis activity and through PDE5 inhibitors such as sildenafil, verdenafil, and tadalafil which can inhibit the hydrolysis of second messenger cGMP of penis smooth muscle cells. Primer Design for amplification of several PDE5 gene nucleotide sequences obtained from NCBI gen banks and tested directly through explosions at NCBI and also using MEGA 6, primer 3 plus, and fast PCR software. The natural treatment of sexual dysfunction through aphrodisiac activity from plants to increase sexual hormone, spermatogenesis activity and inhibitor PDE5 such as sildenafil, vardenafil, and tadalafil can inhibit hydrolysis second messenger of cells cGMP smooth penis muscles. Method: Primer design stages for several sequences are data supply, multiple sequence alignment, sequence trimming, primer design (fastPCR input), in silico PCR analysis, and primer evaluation (Primer Test, OligoCalc and BLAST). Results: Primer of PDE5 that is choosen is with reverse sequence 5-TGCATTGACCATGTCTCTCGTT-3, forward 5-CGCCGATCTGGGCTGAACTA-3 able to amplify template DNA at temperature 67.2°C, 65.8°C, 63.7°C, however, the DNA band fragment looks not very clear, while it is more clearly seen at Tm temperature 61.2°C, 59.1°C, 57.8°C and 57°C. Conclusion: PDE5 primers can be amplified well at temperature 61.2°C, 59.1°C, 57.8°C and 57°C. PDE5 primer succeeded in amplifying DNA with a product length of 402 bp.

S4B-4 A Novel Allosteric Phosphodiesterase 4D Inhibitor BPN14770 Reverses Cognitive Impairment in Humanized PDE4D Mice

Classical inhibitors of PDE4 lack subtype selectivity due to exact amino acid sequence conservation of the catalytic site,and consequently,development of these drugs has stalled due to dose-limiting side effects of nausea and emesis.While use of subtype-selective inhibitors(i.e.,for PDE4A,B,or D)could overcome this issue,conservation of the catalytic region,to which classical inhibitors bind,limits this approach.The present study examined the effects of BPN14770,an allosteric inhibitor of PDE4D,which binds to a primate-specific,N-terminal region,conferring greater than 260-fold selectivity for PDE4D.BPN14770 was 100-fold more potent for improving memory and cognition in humanized PDE4D(hPDE4D)mice,which expressed the primate-specific binding sequence,compared to wild-type mice;meanwhile,it exhibited low potency in a mouse surrogate model for emesis.The behavioral and matching neurochemical data presented established a relationship between PDE4D target engagement and effects on cognition for BPN14770.Furthermore,BPN14770 reversed memory and cognitive deficits induced byβ-amyloid peptide 1-42(Aβ42)in Morris water maze,Y maze and novel object recognition tests in the humanized PDE4D mice.The morphological analyses suggested that the number of dendrites and the dendritic length in the CA1 of hippocampus were significantly increased after the Aβ42-treated hPDE4D mice were administered of BPN14770 for two weeks.The neurochemical and molecular biological assays suggested that neuroplasticity-related proteins and neurotrophic factor BDNF in the hippocampus of hPDE4D mice were significantly increased after the hPDE4D mice were treated with BPN14770.These findings suggest clinical potential for PDE4D selective inhibitors in disorders with cognitive deficits such as Alzheimer’s disease,which affects approximately 20 million people worldwide and nearly 5 million people in the United States.

负压吸引联合PDE-5i治疗糖尿病性勃起功能障碍的临床观察

目的:探讨针对糖尿病性勃起功能障碍(DIED),负压吸引装置(VED)与PDE-5i联合治疗的有效性与安全性。方法:抽取60例DIED患者,采用随机数字表法随机分成治疗组和对照组,每组各30例,对照组:他达拉非5 mg,口服,每日1次,1个疗程为8周。治疗组:他达拉非5 mg,口服,每日1次,在此治疗的基础上联合VED(每周3次,连续8周)治疗;观察患者的IIEF-5评分,未勃起时阴茎长度和周径,勃起硬度等级,患者和配偶在治疗前和治疗后的性生活满意度。结果:对照组治疗后阴茎长度和周径无明显改善(P>0.05);经治疗组处理后,上述指标较以前有所改善(P<0.05)。两组患者治疗后IIEF-5评分、阴茎勃起硬度和患者及配偶满意度均较治疗前有所提高(P<0.05),与对照组(P<0.05)相比,治疗组(P<0.05)的改善程度明显优于对照组,两组间差异有统计学意义(P<0.05)。结论:负压吸引联合PDE-5i治疗方案能使DIED患者阴茎长度和周径及勃起硬度有明显改善,其IIEF-5评分提高,使患者及配偶对性生活满意度提高,对勃起信心增强,疗效确切,无明显副作用,是目前临床上较好的治疗方法之一,值得临床推广应用。

新型吡唑并[3,4-d]嘧啶-4-酮类PDE5抑制剂的合成及其活性研究

设计并合成了一系列以吡唑并[3,4-d]嘧啶-4-酮为母核的PDE5抑制剂。通过放射性同位素法测定了其对PDE5的抑制活性,并计算半数有效抑制浓度(IC_(50)),随后对目标化合物进行了PDEs亚型选择性评价。化合物结构经核磁共振及质谱表征确认。活性评价结果显示,所合成的化合物对PDE5均具有一定的抑制活性,其中6-苄基-1-(4-苯基丁基)-1,5-二氢-4 H-吡唑并[3,4-d]嘧啶-4-酮表现出最强的PDE5抑制活性,其IC_(50)达到90 nmol/L,具有发展成为PDE5抑制剂的潜力。

Effects of phosphodiesterase 5 inhibitors on sperm parameters and fertilizing capacity

The aim of this review study is to elucidate the effects that phosphodiesterase 5 （PDE5） inhibitors exert on spermatozoa motility, capacitation process and on their ability to fertilize the oocyte. Second messenger systems such as the cAMP/adenylate cyclase （AC） system and the cGMP/guanylate cyclase （GC） system appear to regulate sperm functions. Increased levels of intracytosolic cAMP result in an enhancement of sperm motility and viability. The stimulation of GC by low doses of nitric oxide （NO） leads to an improvement or maintenance of sperm motility, whereas higher concentrations have an adverse effect on sperm parameters. Several in vivo and in vitro studies have been carried out in order to examine whether PDE5 inhibitors affect positively or negatively sperm parameters and sperm fertilizing capacity. The results of these studies are controversial. Some of these studies demonstrate no significant effects of PDE5 inhibitors on the motility, viability, and morphology of spermatozoa collected from men that have been treated with PDE5 inhibitors. On the other hand, several studies demonstrate a positive effect of PDE5 inhibitors on sperm motility both in vivo and in vitro. In vitro studies of sildenafil citrate demonstrate a stimulatory effect on sperm motility with an increase in intracellular cAMP suggesting an inhibitory action of sildenafil citrate on a PDE isoform other than the PDE5. On the other hand, tadalafil＇s actions appear to be associated with the inhibitory effect of this compound on PDE11. In vivo studies in men treated with vardenafil in a daily basis demonstrated a significantly larger total number of spermatozoa per ejaculate, quantitative sperm motility, and qualitative sperm motility; it has been suggested that vardenafil administration enhances the secretory function of the prostate and subsequently increases the qualitative and quantitative motility of spermatozoa. The effect that PDE5 inhibitors exert on sperm parameters may lead to the improvement of the outcome of assisted reproductive technology （ART） programs. In the future PDE5 inhibitors might serve as adjunct therapeutical agents for the alleviation of male infertility.

Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP^+ -induced decline of mitochondrial membrane potential and oxidative stress

Parkinson disease(PD) is a chronic neurodegenerative disorder caused by progressive dopaminergic neuronal death in the substantia nigra pars compacta within the midbrain.There still is no cure,effective treatments for PD,available therapies are only capable of offering temporary and symptomatic relief to the patients.There are certain patents that claim phosphodiesterase(PDE) inhibitors as possible anti-PD drugs,PDE4 is a promising target for the treatment of PD and the underlying mechanism has not yet been well elucidated.PDE4 is an enzyme that specifically hydrolyzes intracellular cyclic adenosine monophosphate(cAMP)throughout the body,including the brain.Most of the available PDE4 inhibitors exert unpleasant and serious side effects,such as emesis and nausea,which hinder its clinical application.Therefore,more efforts are needed before PDE4 inhibitors with high therapeutic indices are available for treatment of PD.FCPR16 is a novel PDE4 inhibitor with little emetic potential,which exhibits excellent enzyme inhibition activity(IC50=90 nmol·L^(-1)).METHODS SH-SY5 Y cell was induced with 1-methyl-4-phenylpyridinium(MPP+)to mimic PD cell injury in vitro,and CCK-8 assay was used to investigate the viability effects of different concentration of FCPR16(3.1-50 μmol·L^(-1)) on MPP+-injured SH-SY5 Y cells.Detection of apoptosis was performed by flow cytometry.The level of ntracellular reactive oxygen species was detected with the fluorescent probe DCFH-DA,and the mitochondrial membrane potential of cells in different experimental groups was detected with the JC-1 fluorescent probe.AO staining and Lysotracker Red staining were used to detect the intracellular antophagy changes.The expression of apoptosis related proteins,autophagy and other related signal molecules were demonstrated by Western blotting.Different cellular signaling pathway inhibitors were used to invesitigate the specific cellular mechanisms of FCPR16 protecting MPP+-induced cell injury.RESULTS FCPR16(12.5-50 μmol·L^(-1)) dose-dependently reduced MPP+-induced decline of cell viability,accompanied by reductions in nuclear condensation and lactate dehydrogenase release.The level of cleaved caspase 3 and the ratio of Bax/Bcl-2 were also decreased after treatment with FCPR16 in MPP+-treated cells.Furthermore,FCPR16(25 μmol·L^(-1)) significantly suppressed the accumulation of reactive oxygen species(ROS),prevented the decline of mitochondrial membrane potential(Δψm) and attenuated the expression of malonaldehyde level.Further studies disclosed that FCPR16 enhanced the levels of cA MP and the exchange protein directly activated by cA MP(Epac) in SHSY5 Y cel s.Western blotting analysis revealed that FCPR16 increased the phosphorylation of c AMP response element-binding protein(CREB) and protein kinase B(Akt)down-regulated by MPP+in SHSY5 Y cells.Moreover,the inhibitory effects of FCPR16 on the production of ROS and Δψm loss could be blocked by PKA inhibitor H-89 and Akt inhibitor KRX-0401.CONCLUSION The novel PDE4 inhibitor FCPR16 can protect against damaging pathways including oxidative stress,mitochondrial dysfunction and apoptosis in SH-SY5 Y cells.FCPR16 preventes MPP+-induced neurotoxicity through activation of cAMP/PKA/CREB and Epac/Akt signaling pathways.These may lead to develop mechanism based therapeutics and improved pharmacotherapy for PD.It is reasonable to assume that FCPR16 is a potential candidate for the prevention and treatment of PD.

Luteolin prevents f MLP-induced neutrophils adhesion via suppression of LFA-1 and phosphodiesterase 4 activity

Luteolin is an active ingredient found early from Fofium perillae and Flos Ionicerae, and has a specific inhibition on phosphodiesterase 4 （PDE4） activity in vitro. Researches show luteolin has pharmacological effects of anti-inflammation, anti-anaphylaxis, antitumor, antioxidant, protection of nervous system and so on, and has mainly been used for the treatment of respiratory inflammatory diseases, cancer and cardiovascular disease in clinic. PDE4, specific to hydrolyze cyclic AMP （cAMP）, is considered to be a new anti-inflammatory target due to the decisive role on cAMP signal in inflammatory cells such as neutrophils. In order to explore the anti-inflammatory mechanism, we further studied the effects of luteolin on the activity and expression of PDE4, the expression of lymphocyte function-associated antigen-1 （LFA-1） and macrophage-1 （MAC-l） in neutrophils, and the adhesion of neutrophils and endothelial cells. The results showed that luteolin had a dose-dependent inhibition on both bare PDE4 activity and PDE4 in cultured neutrophils, and had an obviously promotive effect on gene expressions of PDE4A, 4B and 4D in later period. Luteolin had a significant inhibitory effect on neutrophils adhesion and LFA-1 expression in early stage, and had no obvious effect on MAC-1 expression. Therefore, luteolin can inhibit LFA-1 expression of neutrophils, then inhibit the adhesion of neutrophils and endothelial cells, and the mechanism is at least related with the inhibition of PDE4 activity.

Influence of gallic acid on porcine neutrophils phosphodiesterase 4,IL-6,TNF-α and rat arthritis model

Our previous studies showed that the anti-inflammatory effects of Paeonia lactiflora roots extract may be mediated, at least in part, through its gallic acid content, and this effect may be regulated in part by an inhibition on c AMP-phosphodiesterase（PDE）. To explore the anti-inflammatory effect and mechanism, the influence of gallic acid on neutrophils PDE4 activity and expression, TNF-α and IL-6 content and rat arthritis model were further studied. PDE4 activity and gene express were calculated respectively by substrate c AMP change examined with HPLC and real-time RT-PCR. The concentration of IL-6 and TNF-α in supernatant were assayed by ELISA method. Model of rat arthritis was caused by complete Freund＇s adjuvant. Results showed that gallic acid had a dose-dependent restraint on PDE4 activity of neutrophils in vitro, promoted significantly PDE4 A expression（P〈0.01）, and had no influence on the expressions of PDE4 B and 4D. However, PDE4 C expression was not detected. Gallic acid could promote IL-6 release（P〈0.05）, and inhibit TNF-α release of neutrophils（P〈0.05）. The experiment in vivo showed that gallic acid had obvious restraint on local inflammation of animal model（P〈0.05）. Therefore, the anti-inflammatory effect of gallic acid may be mediated in part through an inhibition on PDE4 activity and further an increase of IL-6 and a decrease of TNF-α of neutrophils, and this effect seemed to have no relationship with PDE4 expression.

Diabetic nephropathy:Treatment with phosphodiesterase type 5 inhibitors

The importance of nitric oxide(NO) in vascular physiology is irrefutable;it stimulates the intracellular production of cyclic guanosine monophosphate(cGMP),initiating vascular smooth muscle relaxation.This biochemical process increases the diameter of small arteries,regulating blood flow distribution between arterioles and the microvasculature.The kidney is no exception,since NO predominantly dilates the glomerular afferent arterioles.It is now evident that the vascular production of cGMP can be augmented by inhibitors of phosphodiesterase type 5(PDE 5),the enzyme which breakdowns this cyclic nucleotide.This has clinical relevance,since diabetic nephropathy(DN) a major microvascular complication of diabetes mellitus and the most common cause of end-stage renal disease,increases intraglomerular capillary pressure,leading to glomerular hypertension.PDE 5 inhibitors may have,therefore,the potential to reduce glomerular hypertension.This review describes the use of PDE 5 inhibitors to improve the metabolic,haemodynamic and inflammatory pathways/responses,all of which are dysfunctional in DN.

Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors： retrospective analysis

The purpose of this study was to determine the incidence rate of prostate cancer among men with erectile dysfunction （ED） treated with phosphodiesterase type 5 inhibitors （PDE-5i） over a 7-year period vs. men with ED of the same age and with similar risk factors who were not treated with PDE-5i. In a retrospective review of electronic medical records and billing databases between the years 2000 and 2006, men with ED between the ages of 50 and 69 years and no history of prostate cancer prior to 2000 were identified. These individuals were divided into two groups： 2362 men who had treatment with PDE-5i, and 2612 men who did not have treatment. Demographic data in each group were compared. During the study period, 97 （4.1%） men with ED treated with PDE-5i were diagnosed with prostate cancer compared with 258 （9.9%） men with ED in the non-treated group （P〈00001）. A higher percentage of African Americans were treated with PDE-5i vs. those who were not （10.5% vs. 7.1%; P〈O.O001）. The PDE-5i group had lower documented diagnosis of elevated prostate-specific antigen （10.0% vs. 13.1%; P=-0.0008） and higher percentage of benign prostatic hyperplasia （38.4% vs. 35.1%; P=0.0149）. Men with ED treated with PDE-5i tended to have less chance （adjusted odds ratio： 0.4; 95% confidence intervals： 0.3-0.5; P〈0.0001） of having prostate cancer. Our data suggest that men with ED treated with PDE-5i tended to have less of a chance of beine diaenosed with orostate cancer. Further research is warranted.